Last reviewed · How we verify
SHR2554 tablet dosing
At a glance
| Generic name | SHR2554 tablet dosing |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PHASE2)
- Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR2554 tablet dosing CI brief — competitive landscape report
- SHR2554 tablet dosing updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI